CIK 0001701108 · Non-accelerated filer<br>Smaller reporting company
Spero Therapeutics, Inc.
Sign in to watch- Ticker
- SPRO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-242-1600
- Business address
- 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139
- Former names
- Spero Therapeutics, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $42,485
- in 1 filing
Net −$42,485. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 95 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-08-29 | Shukla Sath Chief Financial Officer | Sale | −6,017 | $0.89 | $5K | 56,064 |
| 2022-04-26 | Aquilo Capital Management, LLC 10% owner | Purchase | +39,727 | $5.24 | $208K | 5,321,231 |
| 2022-03-30 | Aquilo Capital Management, LLC 10% owner | Purchase | +33,115 | $8.79 | $291K | 5,264,619 |
| 2022-03-30 | Aquilo Capital Management, LLC 10% owner | Purchase | +16,885 | $8.79 | $148K | 5,281,504 |
| 2022-03-14 | Aquilo Capital Management, LLC 10% owner | Purchase | +15,702 | $7.63 | $120K | 5,223,498 |
| 2022-03-14 | Aquilo Capital Management, LLC 10% owner | Purchase | +8,006 | $7.63 | $61K | 5,231,504 |
| 2022-02-28 | Aquilo Capital Management, LLC 10% owner | Purchase | +29,729 | $9.53 | $283K | 5,192,692 |
| 2022-02-28 | Aquilo Capital Management, LLC 10% owner | Purchase | +15,104 | $9.53 | $144K | 5,207,796 |
| 2022-02-18 | Aquilo Capital Management, LLC 10% owner | Purchase | +14,828 | $9.24 | $137K | 5,162,963 |
| 2022-02-01 | Melnick David A. Chief Medical Officer | Grant or award | +38,014 | 62,081 | ||
| 2022-02-01 | Melnick David A. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +53,190 | 53,190 | ||
| 2022-02-01 | Shukla Sath Chief Financial Officer | Grant or award | +38,014 | 62,081 | ||
| 2022-02-01 | Shukla Sath Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +53,190 | 53,190 | ||
| 2022-02-01 | Larkin Cristina Chief Operating Officer | Grant or award | +38,014 | 63,581 | ||
| 2022-02-01 | Larkin Cristina Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +53,190 | 53,190 | ||
| 2022-02-01 | Mahadevia Ankit CEO and President | Grant or award | +134,168 | 278,204 | ||
| 2022-02-01 | Mahadevia Ankit CEO and President | Grant or award · Stock Option (Right to Buy) | +187,730 | 187,730 | ||
| 2022-02-01 | Keutzer Timothy Chief Development Officer | Grant or award | +38,014 | 64,581 | ||
| 2022-02-01 | Keutzer Timothy Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +53,190 | 53,190 | ||
| 2022-02-01 | JOSEPH TAMARA L Chief Legal Officer | Grant or award | +38,014 | 62,081 |
Page 7 of 8 · 157 trades